0001193125-22-294013.txt : 20221129 0001193125-22-294013.hdr.sgml : 20221129 20221129102533 ACCESSION NUMBER: 0001193125-22-294013 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20221129 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20221129 DATE AS OF CHANGE: 20221129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vor Biopharma Inc. CENTRAL INDEX KEY: 0001817229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39979 FILM NUMBER: 221429181 BUSINESS ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-655-6580 MAIL ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 8-K 1 d426366d8k.htm 8-K 8-K
false 0001817229 0001817229 2022-11-29 2022-11-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 29, 2022

 

 

Vor Biopharma Inc.

(Exact name of registrant as specified in its Charter)

 

 

 

Delaware   001-39979   81-1591163

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

100 Cambridgepark Drive  
Suite 400  
Cambridge, Massachusetts   02140
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 655-6580

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   VOR   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 7.01

Regulation FD Disclosure.

At the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, Vor Biopharma Inc. confirmed that the VOR33 data it plans to announce later this year will include engraftment data and hematological protection data following treatment with Mylotarg in at least one patient.

The information furnished under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the registrant, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Vor Biopharma Inc.
Date: November 29, 2022     By:  

/s/ Robert Ang

      Robert Ang
      Chief Executive Officer
 EX-101.SCH 2 vor-20221129.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 vor-20221129_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 vor-20221129_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 29, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001817229
Document Type 8-K
Document Period End Date Nov. 29, 2022
Entity Registrant Name Vor Biopharma Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39979
Entity Tax Identification Number 81-1591163
Entity Address, Address Line One 100 Cambridgepark Drive
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02140
City Area Code (617)
Local Phone Number 655-6580
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol VOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 d426366d8k_htm.xml IDEA: XBRL DOCUMENT 0001817229 2022-11-29 2022-11-29 false 0001817229 8-K 2022-11-29 Vor Biopharma Inc. DE 001-39979 81-1591163 100 Cambridgepark Drive Suite 400 Cambridge MA 02140 (617) 655-6580 false false false false Common Stock, $0.0001 par value per share VOR NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d426366d8k.htm vor-20221129.xsd vor-20221129_lab.xml vor-20221129_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d426366d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d426366d8k.htm" ] }, "labelLink": { "local": [ "vor-20221129_lab.xml" ] }, "presentationLink": { "local": [ "vor-20221129_pre.xml" ] }, "schema": { "local": [ "vor-20221129.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vor", "nsuri": "http://vorbiopharma.com/20221129", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d426366d8k.htm", "contextRef": "duration_2022-11-29_to_2022-11-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d426366d8k.htm", "contextRef": "duration_2022-11-29_to_2022-11-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vorbiopharma.com//20221129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-22-294013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-294013-xbrl.zip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end